Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-05-06
1999-10-26
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 9, 530317, 530328, 435 691, A61K 3808, C07K 700
Patent
active
059728930
ABSTRACT:
A method of treating hyperprolactinemia in an animal, including a human, administers one or more somatostatin type-5 receptor agonist(s) to, for example, lower abnormally high levels of prolactin in the blood of the animal. A method of treating a subject, including a human, afflicted by a prolactinoma, administers one or more type-5 receptor selective agonist(s) to, for example, lower prolactin secretion and/or decrease tumor size in the subject.
REFERENCES:
patent: 5424289 (1995-06-01), Yang et al.
patent: 5686418 (1997-11-01), Culler
PCT International Search Report.
Shimon, I. et al., "Somatostatin Receptor Subtype Specificity in Human Fetal Pituitary Cultures", J. Clin. Invest., 99(4): 789-798, Feb. 1997.
Han et al., Can. Res. vol. 47, pp. 1566-1570, Mar. 1987.
Goodman & Gilman's (6th Ed. MacMillan Publishing Co. 1980) Chapter 1, pp. 5-7.
Redding et al PNASUSA 80 pp. 1078-1082 (Feb. 1983).
Koper et al. Canc. Res. 50 6238-42 (Oct. 1990).
Lamberts et al. Acta Endocrinol (Copenh) 1987 115 pp. 196-202.
Shimon et al. J. Clin Invest (Nov. 1997) 100 No. 9 pp. 2386-2392.
Culler Michael D.
Melmed Shlomo
Shimon Ilan
Cedars-Sinai Medical Center
Celsa Bennett
LandOfFree
Method of treating hyperprolactinemia and prolactinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating hyperprolactinemia and prolactinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating hyperprolactinemia and prolactinomas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764494